These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
557 related articles for article (PubMed ID: 21531154)
1. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Farmaki K; Tzoumari I; Pappa C Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154 [TBL] [Abstract][Full Text] [Related]
2. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219 [TBL] [Abstract][Full Text] [Related]
3. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Daar S; Pathare AV Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126 [TBL] [Abstract][Full Text] [Related]
4. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651 [TBL] [Abstract][Full Text] [Related]
5. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Marsella M; Borgna-Pignatti C Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709 [TBL] [Abstract][Full Text] [Related]
6. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233 [TBL] [Abstract][Full Text] [Related]
7. Combined iron chelation therapy. Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777 [TBL] [Abstract][Full Text] [Related]
8. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Kolnagou A; Kontoghiorghes GJ Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649 [TBL] [Abstract][Full Text] [Related]
9. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Gamberini MR; De Sanctis V; Gilli G Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172 [TBL] [Abstract][Full Text] [Related]
10. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620 [TBL] [Abstract][Full Text] [Related]
11. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906 [TBL] [Abstract][Full Text] [Related]
12. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia. Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825 [TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine. Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124 [TBL] [Abstract][Full Text] [Related]
14. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357 [TBL] [Abstract][Full Text] [Related]
17. Treatment of iron overload in thalassemia. Cianciulli P Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study. Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854 [TBL] [Abstract][Full Text] [Related]
19. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Wu KH; Chang JS; Tsai CH; Peng CT Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011 [TBL] [Abstract][Full Text] [Related]
20. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload. Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]